Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease

1. Eknoyan G, Lameire N, Barsoum R. The burden of kidney disease: improving global outcomes. Kidney Int 2004; 66: 1310-4.10.1111/j.1523-1755.2004.00894.xSearch in Google Scholar

2. Block GA, Cunningham J. Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD. In: Olgard K (ed). Clinical Guide to the Basics of Bone and Mineral Metabolism in CKD. National Kidney Foundation: New York, 2006, 77-92.Search in Google Scholar

3. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2006; 69: 1945-53.10.1038/sj.ki.5000414Search in Google Scholar

4. Ersoy FF, Passadakis SP, Tam P, Mammos ED, Katopodis PK, Ozener C et al. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab 2006; 24(1): 79-86.10.1007/s00774-005-0650-3Open DOISearch in Google Scholar

5. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18(2) : 75-85.10.1016/8756-3282(95)00445-9Open DOISearch in Google Scholar

6. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest 1996; 97: 2692-6.10.1172/JCI1187225073608675678Open DOISearch in Google Scholar

7. Liberman UA, Weiss SR, Broll J. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-43.10.1056/NEJM1995113033322017477143Search in Google Scholar

8. Lomashvili KA, MonierFaugere MC, Wang X, Malluche HH, O’Neill WC. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009; 75(6): 617-25.10.1038/ki.2008.646299957719129793Search in Google Scholar

9. Trabulus S, Altiparmak MR, Apaydin S. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol and alendronate combined with alfacalcidol. Transplant Proc 2008; 40: 160-6.10.1016/j.transproceed.2007.12.00118261575Search in Google Scholar

10. Negri AL. Vascular calcifications in chronic kidney disease: are there new treatments? Current Vascular Pharmacology. 2005; 3(2): 181-4.10.2174/157016105358687715853637Search in Google Scholar

11. Liu S, Gupta A, Quarles LD. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 2007; 16: 329-35.10.1097/MNH.0b013e3281ca6ffd17565275Search in Google Scholar

12. Klawansky S, Komaroff E, Cavanaugh PFJ, Mitchell DY, Gordon MJ, Connelly JE et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int 2003; 14: 570-6.10.1007/s00198-003-1435-y12844211Search in Google Scholar

13. Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L et al. Population based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 2004; 19(12): 1945-54.10.1359/jbmr.040916Search in Google Scholar

14. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993; 76: 1399-406.Search in Google Scholar

15. Wetmore JB, Benet LZ, Kleinstuck D, Frassetto L. Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrol 2005; 10(4): 393-9.10.1111/j.1440-1797.2005.00436.x16109088Search in Google Scholar

16. Shahbazian H, Tamadon MR, Mowla SK, Shayanpour S, Hayati F, Shojaii M et al. Effect and safety of alendronate on bone density in patients with chronic kidney disease; a controlled double blind randomized clinical trial. J Parathyroid Dis 2016; 4(1): 3-6.Search in Google Scholar

17. Shahbazian H, Mowla K, Shahbazian HB, Peydayesh B, Ehsanpour A. Efficacy and safety of alendronate in the prevention of bone loss in renal transplant recipients. Indian J Nephrol 2007; 17: 61-510.4103/0971-4065.37022Search in Google Scholar

18. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A et al.. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007; 22(4): 503-8.10.1359/jbmr.07011217243862Search in Google Scholar

19. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004; 89(9): 4246-53.10.1210/jc.2003-03096415356016Search in Google Scholar

20. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 2010; 56(1): 57-68.10.1053/j.ajkd.2009.12.03920347511Search in Google Scholar

21. Ylitalo R, Kalliovalkama J, Wu X, Kankaanranta H, Salenius JP, Lahteenmaki T et al. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol. 1998; 83: 125-31.10.1111/j.1600-0773.1998.tb01455.x9783331Search in Google Scholar